Details for Patent: 7,851,509
✉ Email this page to a colleague
Which drugs does patent 7,851,509 protect, and when does it expire?
Patent 7,851,509 protects ZOLINZA and is included in one NDA.
This patent has ninety patent family members in twenty-eight countries.
Summary for Patent: 7,851,509
Title: | Polymorphs of suberoylanilide hydroxamic acid |
Abstract: | The present invention provides methods of selectively inducing terminal differentiation, cell growth arrest and/or apoptosis of neoplastic cells, and/or inhibiting histone deacetylase (HDAC) by administration of pharmaceutical compositions comprising potent HDAC inhibitors. The oral bioavailability of the active compounds in the pharmaceutical compositions of the present invention is surprisingly high. Moreover, the pharmaceutical compositions unexpectedly give rise to high, therapeutically effective blood levels of the active compounds over an extended period of time. The present invention further provides a safe, daily dosing regimen of these pharmaceutical compositions, which is easy to follow, and which results in a therapeutically effective amount of the HDAC inhibitors in vivo. The present invention also provides a novel Form I polymorph of SAHA, characterized by a unique X-ray diffraction pattern and Differential Scanning Calorimetry profile, as well a unique crystalline structure. |
Inventor(s): | Miller; Thomas A. (Brookline, MA), Richon; Victoria M. (Wellesley, MA) |
Assignee: | Merck HDAC Research, LLC (Boston, MA) |
Application Number: | 12/077,396 |
Patent Claim Types: see list of patent claims | Composition; Dosage form; Use; Formulation; |
Drugs Protected by US Patent 7,851,509
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Msd Sub Merck | ZOLINZA | vorinostat | CAPSULE;ORAL | 021991-001 | Oct 6, 2006 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | TREATMENT OF CUTANEOUS MANIFESTATIONS IN PATIENTS WITH CUTANEOUS T-CELL LYMPHOMA (CTCL) | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 7,851,509
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Austria | 462426 | ⤷ Try a Trial | |||
Australia | 2003213684 | ⤷ Try a Trial | |||
Australia | 2004266169 | ⤷ Try a Trial | |||
Australia | 2004283717 | ⤷ Try a Trial | |||
Australia | 2008246251 | ⤷ Try a Trial | |||
Australia | 2009201668 | ⤷ Try a Trial | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |